AI assistant
Avidity Biosciences, Inc. — Director's Dealing 2021
Jun 17, 2021
30894_dirs_2021-06-16_d188cef9-7d96-423a-95ba-0bc688ce0913.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Avidity Biosciences, Inc. (RNA)
CIK: 0001599901
Period of Report: 2021-06-14
Reporting Person: LEVIN ARTHUR A (Chief Scientific Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2021-06-14 | Common Stock | S | 14003 | $25.9174 | Disposed | 23019 | Indirect |
| 2021-06-15 | Common Stock | S | 23019 | $26.0249 | Disposed | 0 | Indirect |
Footnotes
F1: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $25.70 to $26.06. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F2: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $25.62 to $26.47. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.